Sign In
Buy FLGT
$18.14
-0.560 (-2.99%)
At Close: Jun 03, 2026
8 High-Risk Stocks to Buy That Are Worth Taking a Chance On
10:11am, Friday, 18'th Jun 2021
High-growth stocks aren't bothered by inflation like their big-cap brethren. Here are some high-risk stocks with plenty to offer investors.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
06:48pm, Thursday, 17'th Jun 2021
In the latest trading session, FULGENT GENETIC (FLGT) closed at $75.69, marking a +1.16% move from the previous day.
Revisiting a Top Contrarian Stock Pick of 2021
08:14am, Thursday, 17'th Jun 2021
As we kicked off 2021, we highlighted two top contrarian picks for the new year.
Fulgent Genetics: Get In Early Before It Starts To Take Off
02:31pm, Sunday, 13'th Jun 2021
Fulgent is one of the emerging players in the highly fragmented genetic testing market. The company astutely strengthened its credibility and proved its capability by playing a key role in COVID-19 te
7 Healthcare Stocks to Buy for Changing Demographics
11:36am, Friday, 11'th Jun 2021
These seven healthcare stocks are in a good position to take off as baby boomers continue to age into retirement. The post 7 Healthcare Stocks to Buy for Changing Demographics appeared first on Invest
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
06:47pm, Wednesday, 09'th Jun 2021
In the latest trading session, FULGENT GENETIC (FLGT) closed at $84, marking a +0.1% move from the previous day.
8 Stocks With The Highest Short Interest
03:00pm, Wednesday, 02'nd Jun 2021
Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding sh
How Long Will Fulgent Genetics Benefit From the Pandemic?
12:45pm, Saturday, 29'th May 2021
Genetic testing for the coronavirus is slowing.
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
02:52pm, Sunday, 16'th May 2021
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma
What Are Investors Thinking About Fulgent Genetics?
07:10am, Friday, 14'th May 2021
Hint: It has something to do with COVID-19.
Fulgent Genetics Has Another Blast Out Quarter
09:29am, Wednesday, 12'th May 2021
Fulgent Genetics Has Another Blast Out Quarter
Fulgent Genetics: How Cash Could Be Deployed And Underlying Implications
09:19am, Monday, 10'th May 2021
Fulgent's Q2 2021 guidance is strong, but that implies that H2 2021 will not be very alluring. Bears are too dismissive of Fulgent's approximately $1 billion in cash on its balance sheet by year-end.
Why Investors Loved Fulgent Genetics' Q1 Results
06:08am, Friday, 07'th May 2021
More than 4,500% revenue growth gave Wall Street and shareholders something to cheer about.
Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q1 2021 Results - Earnings Call Transcript
10:24pm, Thursday, 06'th May 2021
Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q1 2021 Results - Earnings Call Transcript
FULGENT GENETIC (FLGT) Q1 Earnings and Revenues Surpass Estimates
09:47pm, Thursday, 06'th May 2021
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
